Compare NIM & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIM | TTRX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.1M | 107.2M |
| IPO Year | N/A | N/A |
| Metric | NIM | TTRX |
|---|---|---|
| Price | $9.26 | $5.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 20.8K | ★ 27.9K |
| Earning Date | 01-01-0001 | 05-31-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.93 | $2.57 |
| 52 Week High | $9.94 | $5.98 |
| Indicator | NIM | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 77.91 |
| Support Level | $9.23 | $4.11 |
| Resistance Level | $9.44 | $5.55 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 43.75 | 94.03 |
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.